Nalley Lisa A sold $2.1M of BTSG

Nalley Lisa A (See Remarks) sold 35,000 shares of BrightSpring Health Services, Inc. (BTSG) at $58.75 ($2.06M total) on 2026-06-05.

Original reporting
SEC EDGAR · Nalley Lisa A
Published Jun 5, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Neutral
medium confidence
Mentioned
$BTSG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider behavior but does not include new company fundamentals (earnings, guidance, contracts, trials, or litigation).

02

Market read

Traders may briefly reassess sentiment around BTSG, but the event lacks a clear fundamental catalyst.

03

What to watch

Check for other concurrent insider trades, changes in institutional ownership, and whether the sale price ($58.75) differs materially from recent trading levels.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-06-05) insider sale disclosure

Background

This is an SEC Form 4 insider transaction disclosure for BrightSpring Health Services (BTSG).

Company-level read

Ticker impact

$BTSGNeutralMedium confidence
Context

BrightSpring Health Services officer Nalley Lisa A sold 35,000 shares in an open-market transaction worth about $2.06M.

Expected impact

Likely limited/short-lived impact; watch for follow-through if selling volume persists or coincides with other disclosures.

Evidence & confidence

The filing is a routine insider transaction (open-market sale) with no stated 10b5-1 plan and no accompanying operational or financial catalyst in the article.

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Without a stated 10b5-1 plan, the sale could still be routine (tax/portfolio rebalancing) and may not signal deterioration.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the Form 4 insider sale by officer Nalley Lisa A.

  • Nalley Lisa A

    Officer who sold 35,000 shares of BTSG on 2026-06-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGHighAI 8/10

Guggenheim raises BrightSpring Health stock price target on growth

Guggenheim raised its price target on BrightSpring Health Services (BTSG) to $84 from $81, maintaining a Buy rating. The company reported strong Q3 2026 results, with revenue growth of 26% and earnings of $0.54 per share, exceeding expectations. Management expects 15-20% organic EBITDA growth in 2027. Analysts remain optimistic, with a consensus Strong Buy rating and targets ranging from $70 to $92.

$BTSGHighAI 8/10

UBS raises BrightSpring Health stock price target to $92 on growth outlook

UBS increased its price target for BrightSpring Health Services (BTSG) to $92 from $85, citing growth prospects in its Specialty Pharmacy and Infusion businesses. The stock has surged 102% over the past year. The company reported Q3 2026 earnings of $0.54 per share, beating estimates, and raised its 2026 revenue guidance to $15.9B-$16.125B. Goldman Sachs also raised its target to $90, highlighting strong growth.

$BTSGMed

BrightSpring Health Services Inc (BTSG) (Q3 2026) Earnings Call Highlights: Revenue Jumps

BrightSpring Health Services (BTSG) reported Q3 2026 revenue growth of 26%, but Home and Community Pharmacy revenue declined 6% due to IRA impact. CEO Jon Rousseau emphasized broad growth drivers and stability in LDD economics. The company expects IRA to remain a headwind with a $200M total impact. BTSG did not provide specific 2027 guidance, focusing on organic adjusted EBITDA growth. The CEO discussed M&A opportunities, primary care initiatives, and specialty script growth.